Scholarlink

Background <p>BNCT is known as the “fifth therapy” after surgery, traditional radiotherapy, anti-cancer drugs and immunotherapy. It has prominent clinical advantages for brain tumors.</p> Purpose <p>The aim of this study is to reveal the underlying mechanism of BNCT in the treatment of glioblastoma through transcriptome analysis, and to provide new theoretical basis and potential therapeutic targets for its clinical application.</p> Methods <p>The neutron beam was derived from Mazu Branch of the Union Hospital Affiliated to Fujian Medical University. Human glioma cell lines U87 was used to evaluate the cytotoxicity of BNCT. U87 tumor-bearing mice were divided into four groups: Control (untreated); N20 (neutron irradiation only); BPA (500&#xa0;mg/kg BPA only); and 500N20 (500&#xa0;mg/kg BPA plus neutron irradiation). Transcriptome sequencing was used to analyze gene expression profiles, functional enrichment pathways and key regulatory networks after BNCT treatment.</p> Results <p>500N20 has obvious inhibitory effect on U87 subcutaneous tumor. GO and KEGG functional enrichment analysis showed that tumors after BNCT were significantly enriched in cell cycle and cell death pathways. Three cell cycle-related genes FANCI, UHRF1 and BEX2 related to the prognosis of glioma were screened out. In addition, BNCT promotes apoptosis, inhibits ferroptosis, and induces exogenous apoptosis induced by the death receptors FAS and TNFRSF10B.</p> Conclusion <p>BNCT induced cell cycle changes associated with prognostic genes FANCI, UHRF1 and BEX2. BNCT induces extrinsic apoptosis mainly through the pathway of death receptors such as FAS and TNFRSF10B. This study provides potential therapeutic targets and theoretical basis for BNCT clinical treatment of glioma.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Transcriptome sequencing analysis revealed the molecular mechanism of BNCT inhibiting the growth of U87 subcutaneous tumor

  • 期刊论文

  • 发表日期：

    2026年1月5日

查看全文
  • Hefa Huang,
  • Feifei Gao,
  • Rui Quan,
  • Wenming Zhou,
  • Xiaogang Zheng,
  • Ruirong Zhuang,
  • Zhongying Dai,
  • Long Gu,
  • Weiqiang Chen,
  • Lu Zhang

摘要

Background

BNCT is known as the “fifth therapy” after surgery, traditional radiotherapy, anti-cancer drugs and immunotherapy. It has prominent clinical advantages for brain tumors.

Purpose

The aim of this study is to reveal the underlying mechanism of BNCT in the treatment of glioblastoma through transcriptome analysis, and to provide new theoretical basis and potential therapeutic targets for its clinical application.

Methods

The neutron beam was derived from Mazu Branch of the Union Hospital Affiliated to Fujian Medical University. Human glioma cell lines U87 was used to evaluate the cytotoxicity of BNCT. U87 tumor-bearing mice were divided into four groups: Control (untreated); N20 (neutron irradiation only); BPA (500 mg/kg BPA only); and 500N20 (500 mg/kg BPA plus neutron irradiation). Transcriptome sequencing was used to analyze gene expression profiles, functional enrichment pathways and key regulatory networks after BNCT treatment.

Results

500N20 has obvious inhibitory effect on U87 subcutaneous tumor. GO and KEGG functional enrichment analysis showed that tumors after BNCT were significantly enriched in cell cycle and cell death pathways. Three cell cycle-related genes FANCI, UHRF1 and BEX2 related to the prognosis of glioma were screened out. In addition, BNCT promotes apoptosis, inhibits ferroptosis, and induces exogenous apoptosis induced by the death receptors FAS and TNFRSF10B.

Conclusion

BNCT induced cell cycle changes associated with prognostic genes FANCI, UHRF1 and BEX2. BNCT induces extrinsic apoptosis mainly through the pathway of death receptors such as FAS and TNFRSF10B. This study provides potential therapeutic targets and theoretical basis for BNCT clinical treatment of glioma.